Study on endocrine therapy of scirrous type gastric cancer using Medroxyprogesterone acetate

1)。人胃癌组织中雌激素受体的特征。对人胃癌中雌激素受体(ER)的表达进行了研究。细胞悬液为150，40OXg上清液。在胞质中，蔗糖密度梯度显示与ER的5S和8S结合峰。类固醇特异性研究表明，雌激素是雌激素与受体结合的特异性抑制物。ER和PGR均位于胃癌细胞的胞核。ER阳性率为29%，PGR阳性率为10.3%。ER和PGR阳性率与低分化癌、硬化型癌和年轻女性胃癌患者有较高的相关性。接受三苯氧胺治疗的可切除胃癌患者的预后明显好于未接受三苯氧胺治疗的患者。醋酸甲羟孕酮(1×10~(-6)~(-6)~(gt；M)~(-1)×10~(-1)~(-7)~(gt；M))在体内对低度胃癌细胞(Kato III)有抑制作用。

1). Characterization of estrogen receptor in human gastric cancer. Estrogen receptor(ER) in human gastric cancer is characterized. 150,40OXg suppernatant was used as cytozol. In the cytozol, sucrose density gradingts showed 5s and 8s binding peaks for ER. Steroid specificity studies showed that estrogen for estradiol-receptor binding was specific inhibitor.2). Both ER and PgR were located at the nuclei of gastric cancer cells. ER positive rate was 29% and PgR positive rate was 10.3%. ER and PgR positive rate were most likely to be associated with poorly differentiated carcinoma, scirrhous type carcinoma and younger female gastric cancer patients.3). The respectable gastric cancer patients with administration of Tamoxifen showed better prognosis than those without administration of tamoxifen.4). The poorly gastric cancer cells ( KATO III ) were inhibited in vivo by Medroxyprogesterone acetate ( 1x10^<-6>M-1x10^<-7>M ).